The discussion surrounding medicinal cannabis evidence continues to be a prominent topic within Australian healthcare. As patient interest grows, clinicians and policymakers are navigating the evolving regulatory landscape and the scientific data supporting its use. This includes understanding the various pathways to access and the specific conditions for which preliminary research indicates potential benefits.
In Australia, there are several pathways for patients to legally access medicinal cannabis. These include the Category A Special Access Scheme (SAS) for unregistered products on compassionate grounds, and the Category B SAS, which provides access to locally stored medicinal cannabis following Therapeutic Goods Administration (TGA) and state review. Additionally, specialists, such as oncologists for cancer-related pain or paediatric neurologists for severe epilepsy, can obtain Authorised Prescriber status.
The Evolving Landscape of Medicinal Cannabis Evidence
The Royal Australasian College of Physicians (RACP) has adopted a cautious stance, noting that Australia, like other nations, is “navigating unchartered waters with pharmaceutical grade cannabinoids.” The RACP emphasises the ongoing need for robust research to clearly define the place of medicinal cannabis in contemporary medical practice.
Insights from Paediatric Epilepsy Research
For certain conditions, such as paediatric epilepsy, some research is beginning to provide clearer insights. A randomised, double-blind trial of cannabidiol (CBD), a cannabis derivative without psychoactive properties, suggested potential in children with Dravet syndrome, a severe form of childhood epilepsy. This was followed by another trial, published in The Lancet, which indicated similar potential for CBD in Lennox–Gastaut syndrome, another complex paediatric epilepsy.
Laureate Professor Ingrid Scheffer, Chair of Paediatric Neurology Research at The University of Melbourne and a co-author of the Dravet syndrome trial, highlighted that while her study provided evidence for CBD’s potential, it should not be considered a definitive solution. Professor Scheffer noted that cannabidiol achieved a 43% responder rate in their study, defined as at least a 50% reduction in seizure frequency, which is comparable to some other established antiepileptic medications.
Professor Scheffer stressed the importance of further research:
- The variability of products accessed by patients, often from unregulated sources, makes it difficult to ascertain consistent effects or safety.
- More trials are needed across different patient populations and with various formulations to ensure that investments in medicinal cannabis are evidence-based and effective.
Clinical Perspectives on Cannabidiol Use
Dr. John Lawson, a Sydney-based paediatric neurologist and co-author of a Narrative Review on cannabis and childhood epilepsy, shared his evolving perspective. While initially sceptical, Dr. Lawson now considers cannabidiol to be an antiepileptic, though he suggests it is still in early stages of development and its precise role requires further clarification. He noted that he would typically consider it after other antiepileptic medications have proven ineffective.
A significant consideration for patients and clinicians is the cost of TGA-approved medicinal cannabis products. Dr. Lawson mentioned that for a small child, the cost could exceed $1000 every two weeks, making it largely accessible only to those with substantial financial resources. He also observed that while cannabidiol may offer some benefit, patients are rarely seizure-free, and the effect is often modest.
Both Professor Scheffer and Dr. Lawson underscore that while cannabidiol may have a role in the future, particularly for drug-resistant epilepsies, it is not a universal solution. The ongoing need for rigorous clinical trials and a clear understanding of its pharmacology remains paramount to integrate medicinal cannabis into mainstream clinical practice responsibly.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
